{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:04:35Z","timestamp":1791425075818,"version":"4.3.3"},"reference-count":29,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long\u2010term, real\u2010word data are needed to help manage patients with hidradenitis suppurativa (HS) through this recurrent, painful and debilitating disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To primarily measure real\u2010world effectiveness of adalimumab in HS and to secondarily observe clinical course of HS in the light of patients\u2019 response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In SOLACE, adults with moderate\u2010to\u2010severe HS in need for change in ongoing therapy were treated with adalimumab for up to 52\u2009weeks as per physician\u2019s medical practice. Treatment effectiveness was measured by Hidradenitis Suppurativa Clinical Response (HiSCR). Inflammatory nodules, abscesses and draining fistulas were counted, Hurley stage was assessed, and disease severity was rated using the International HS Severity Scoring System (IHS4). A post hoc analysis further explored the HiSCR response by abscess and inflammatory nodule (AN) count at baseline (low, medium and high) and gender. Spontaneously reported safety events were collected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 23 Canadian centres, 69% of the 138 patients achieved HiSCR at week 24, which increased to 82% and 75% at week 52 in patients with medium and high AN counts, respectively. Gender (4 times the odds for female) and age at HS onset (5% decrease with each additional year) had an effect on achieving HiSCR. Treatment with adalimumab led to an important decrease in number of lesions in responders, with most gains observed in inflammatory nodules, more frequently in the lower body area of patients in the high AN count group. The IHS4 scores of responders were substantially lowered, with a larger decrease in patients of the high AN count group. No new safety signal was detected.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The effectiveness of adalimumab was maintained during this 1\u2010year period, and an optimal gain was documented for patients with medium and high AN counts. These real\u2010world data support a prompt treatment of HS patients and the use of IHS4 to monitor treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.17598","type":"journal-article","created":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T04:16:13Z","timestamp":1628655373000},"page":"2431-2439","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Real\u2010world effectiveness of adalimumab in patients with moderate\u2010to\u2010severe hidradenitis suppurativa: the 1\u2010year SOLACE study"],"prefix":"10.1111","volume":"35","author":[{"given":"W.","family":"Gulliver","sequence":"first","affiliation":[{"name":"NewLab Clinical Research Inc. St. John\u2019s NL Canada"},{"name":"Faculty of Medicine Memorial University of Newfoundland St. John\u2019s NL Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alavi","sequence":"additional","affiliation":[{"name":"Department of Dermatology Mayo Clinic Rochester MN USA"},{"name":"Probity Medical Research Inc. Waterloo ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Wiseman","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc. Waterloo ON Canada"},{"name":"Wiseman Dermatology Research Winnipeg MB Canada"},{"name":"Section\u2009of Dermatology Department of Medicine University of Manitoba Winnipeg MB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Gooderham","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc. Waterloo ON Canada"},{"name":"SKiN Centre for Dermatology Peterborough ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rao","sequence":"additional","affiliation":[{"name":"Clinical Professor of Medicine Division of Dermatology University of Alberta Edmonton AB Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Alam","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc. Waterloo ON Canada"},{"name":"SimcoMed Health Ltd Barrie ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"K.A.","family":"Papp","sequence":"additional","affiliation":[{"name":"Probity Medical Research Inc. Waterloo ON Canada"},{"name":"Kim Papp Clinical Research Waterloo ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Desjardins","sequence":"additional","affiliation":[{"name":"AbbVie Corporation Saint\u2010Laurent QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Jean","sequence":"additional","affiliation":[{"name":"AbbVie Corporation Saint\u2010Laurent QC Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000431175"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16677"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17919"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18983"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3520"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13216"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09198.x"},{"key":"e_1_2_6_13_1","volume-title":"Dermatologic Surgery, Principles and Practice","author":"Hurley H","year":"1989"},{"key":"e_1_2_6_14_1","unstructured":"U.S. Food and Drug Administration.FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy. In Vol. 2020. 2018."},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15233"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16023"},{"key":"e_1_2_6_18_1","doi-asserted-by":"crossref","unstructured":"FrewJ JiangC&SinghNet\u00a0al. Clinical Response Rates Placebo Response Rates and Significantly Associated Covariates Are Dependent Upon Choice of Outcome Measure in Hidradenitis Suppurativa: A Post\u2010Hoc Analysis of PIONEER 1 and 2 Individual Patient Data. J Am Acad Dermatol 2020; 82: 1150\u20131157.","DOI":"10.1016\/j.jaad.2019.12.044"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14038"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1301"},{"key":"e_1_2_6_21_1","first-page":"1111","article-title":"Lymecycline versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasound evaluation","volume":"10","author":"Caposiena Caro R","year":"2020","journal-title":"Clin Exp Dermatol"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.05.007"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1159\/000503606"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418823529"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.035"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30564-X"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01145-8"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2019.06.026"},{"key":"e_1_2_6_30_1","first-page":"E98\u2013E102","article-title":"Infection\u2010free Clinical response among patients with hidradenitis suppurativa who were treated with adalimumab: results from two phase 3 studies","volume":"29","author":"Giamarellos\u2010Bourboulis E","year":"2017","journal-title":"Wounds"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17598","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17598","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T07:35:19Z","timestamp":1692948919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/jdv.17598"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17598","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"2021-03-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}